QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1/2 Terminated 43 enrolled Altor BioScience

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.

Timeline

Start: 2015-04-17
Primary completion: 2020-12-13
Completion: 2020-12-13

Publications

Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N-803	Protein / enzyme biologic	1 ug/kg	Intravenous
Subject	N-803	Protein / enzyme biologic	3 ug/kg	Intravenous
Subject	N-803	Protein / enzyme biologic	6 ug/kg	Intravenous
Subject	N-803	Protein / enzyme biologic	10 ug/kg	Intravenous
Subject	N-803	Protein / enzyme biologic	15 ug/kg	Intravenous
Subject	N-803	Protein / enzyme biologic	20 ug/kg	Intravenous
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Summary

Timeline

Publications

Drugs

Indications